Cargando…

Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies

The growth of hematologic malignant cells can be facilitated by other non-tumor cells within the same microenvironment, including stromal, vascular, immune and mesenchymal stem cells. Macrophages are an integral part of the human innate immune system and the tumor microenvironment. Complex interplay...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petty, Amy J., Yang, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952752/ https://www.ncbi.nlm.nih.gov/pubmed/31783588 http://dx.doi.org/10.3390/cells8121526

Ejemplares similares

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
por: Petty, Amy J., et al.
Publicado: (2021)

The Role of Tumor-Associated Macrophages in Hematologic Malignancies
por: Cencini, Emanuele, et al.
Publicado: (2021)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Targeting macrophages in hematological malignancies: recent advances and future directions
por: Li, Wei, et al.
Publicado: (2022)

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
por: Fratta, Elisabetta, et al.
Publicado: (2016)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Macrophage-Based Therapeutic Strategies in Hematologic Malignancies
por: Khalili, Saeed, et al.
Publicado: (2023)

Risk of infection associated with targeted therapies for solid organ and hematological malignancies
por: Ruiz-Camps, Isabel, et al.
Publicado: (2021)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
por: Allegra, Alessandro, et al.
Publicado: (2021)

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
por: Andreescu, Mihaela
Publicado: (2023)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
por: Wolska-Washer, Anna, et al.
Publicado: (2022)

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
por: Zhao, Ailin, et al.
Publicado: (2023)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
por: Petty, Amy J., et al.
Publicado: (2020)

New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies
por: Menzo, Sara Lo, et al.
Publicado: (2015)

Dendritic Cell Therapies for Hematologic Malignancies
por: Weinstock, Matthew, et al.
Publicado: (2017)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy
por: Das, Kaushik, et al.
Publicado: (2023)

Tumor-Associated Macrophages as Target for Antitumor Therapy
por: Sawa-Wejksza, Katarzyna, et al.
Publicado: (2017)

Role of Circulating Tumor DNA in Hematological Malignancy
por: Ogawa, Miho, et al.
Publicado: (2021)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Targeting DNA Repair Pathways in Hematological Malignancies
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8(+) T cell function
por: Petty, Amy J., et al.
Publicado: (2021)

The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options
por: Di Costanzo, Antonella, et al.
Publicado: (2020)

Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies
por: Reagan, John L., et al.
Publicado: (2012)

Tumor Lysis Syndrome in Patients with Hematological Malignancies
por: Belay, Yohannes, et al.
Publicado: (2017)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights
por: Hu, Mingzheng, et al.
Publicado: (2022)

Cancer associated fibroblasts in hematological malignancies
por: Raffaghello, Lizzia, et al.
Publicado: (2014)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
por: Tan, Jing Yuan, et al.
Publicado: (2022)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016)

Defining and targeting tumor-associated macrophages in malignant mesothelioma
por: Wu, Licun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3g64m1sflauk6cn0p4kf0asamu